Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

JAK Inhibitors vs. Biologics: Choosing the Right Atopic Dermatitis Therapy

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma: Key Considerations

What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?

Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs

Identifying Candidates for CAR T-Cell Therapy in Relapsed/Refractory ALL

Inconsistent Outcomes: How Ignoring Guidelines Leads to Unpredictable Results

Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status

No Patient Left Behind! Advancing CKD-Associated Pruritus Care

EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

Continuum of Care: Managing DMD in Pediatric and Adult Patients

Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?

Evaluating First-Line Therapy for Acute
Graft-Versus-Host Disease

JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis: Examining Efficacy and Safety